Nanomedicine, the application of nanoscience and technology to medical research and technology, promises to revolutionize healthcare with advances in diagnostic tests, therapeutics and drug delivery methods. Even though nanomedicine has led to futuristic claims, it has presented exciting breakthroughs in drug research and development. My presentation will highlight a case study, a Phase I study of a commercially promising nano-medicine referred to as CYT 6091. This novel drug is being tested in human beings at the National Cancer Institute. Case study analysis will help us to explore the clinical challenges, ethical issues and social considerations that should be addressed as this technology moves from the bench to the bedside. Thought provoking questions will stimulate discussion such as; is the current model of voluntary informed consent adequate? What does society need to know about new drug delivery devices and nano medicine drugs? Who will benefit from the new ground breaking technologies as they emerge? How will the risks and benefits be shared?

UPenn Center for Bioethics

My primary interest has been research ethics. Recent work has focused on the ethical issues and social implications pertaining to nano science and technology and in particular, the emergence of nanomedicine and human subject’s research. This builds on previous work and research that was completed on institutional review board decision-making. Currently, I am staff and a fellow at the Center for Bioethics at the University of Pennsylvania where I do compliance oversight for the ethical component of the Immune Tolerance Network. My appointment as an assistant professor will be through the School of Nursing at the University of Pennsylvania where I work in the Office of Nursing Research.